Abeona Therapeutics Inc. (ABEO) Income Statement
ABEO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsABEO revenue and net income
Where ABEO's revenue goes
2025Each bar shows an amount and its share of revenue. ABEO kept 1,223.1% of revenue as net income.
ABEO profit margins
ABEO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | +60.3% | −10.3% | +18.8% |
| Gross profit | — | +64.5% | −15.6% | +15.2% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ABEO quarterly EPS vs estimates
Abeona Therapeutics beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.14).
ABEO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $0 | $3.5M | $1.4M | $3.0M | $10.0M | $0 | $3.0M | $837,000 | $889,000 |
| Cost of revenue | $1.5M | $2.9M | $1.6M | $450,000 | $38.7M | $30.1M | $48.6M | $38.7M | $17.0M | $10.7M |
| Gross profit | $4.3M | −$2.9M | $1.9M | $964,000 | $3.0M | $10.0M | −$48.6M | −$35.7M | −$16.2M | −$9.8M |
| Research & development | $26.8M | $34.4M | $31.1M | $29.0M | $38.7M | $30.1M | $53.8M | $38.7M | $17.0M | $10.7M |
| Sales, general & admin | $65.0M | $29.9M | $19.0M | $17.3M | $21.6M | $23.8M | $20.7M | $20.1M | $10.9M | $13.3M |
| Total operating expenses | $93.7M | $61.3M | $49.0M | $51.9M | $92.8M | $91.4M | $28.5M | $61.2M | $28.7M | $24.8M |
| Operating income | −$89.4M | −$64.2M | −$47.1M | −$50.9M | −$89.8M | −$81.4M | −$77.1M | −$58.2M | −$27.8M | −$23.9M |
| Interest income | $5.6M | $4.2M | $2.1M | $431,000 | $69,000 | $1.3M | $1.2M | $1.5M | $525,000 | $2.0M |
| Interest expense | $3.7M | $4.2M | $418,000 | $736,000 | $3.7M | $4.1M | $400,000 | $11,000 | $8,000 | $6,000 |
| Income before taxes | $71.3M | −$63.7M | −$54.2M | −$39.7M | −$84.9M | −$84.2M | −$76.3M | −$56.7M | −$27.3M | −$21.9M |
| Income taxes | $100,000 | — | $3.0M | −$7.9M | $3.7M | $4.1M | $400,000 | $1.5M | $525,000 | $2.0M |
| Net income | $71.2M | −$63.7M | −$54.2M | −$39.7M | −$84.9M | −$84.2M | −$76.3M | −$56.7M | −$27.3M | −$21.9M |
| EBITDA | $78.6M | −$56.6M | −$50.6M | −$34.4M | −$76.8M | −$74.5M | −$68.4M | −$54.3M | −$26.6M | −$21.0M |
| EPS (diluted) | −$1.19 | −$1.91 | −$2.37 | −$5.53 | −$15.27 | −$13.86 | −$38.25 | −$29.75 | −$16.50 | −$16.00 |
| Gross margin | 73.7% | — | 54.1% | 68.2% | 100.0% | 100.0% | — | −1,190.8% | −1,929.7% | −1,098.5% |
| Operating margin | −1,536.9% | — | −1,346.7% | −3,600.8% | −2,994.5% | −814.2% | — | −1,940.2% | −3,325.7% | −2,686.3% |
| Net margin | 1,223.1% | — | −1,548.2% | −2,807.4% | −2,831.2% | −842.3% | — | −1,890.3% | −3,263.9% | −2,460.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.4M | $8.7M | $5.4M | $0 | $400,000 | $0 | $4.8M | $0 | $0 | $0 | $2.8M | $0 |
| Cost of revenue | $4.2M | $3.6M | $2.8M | $488,000 | $100,000 | $815,000 | $776,000 | $722,000 | $1.7M | $724,000 | $721,000 | $30,000 |
| Gross profit | $7.2M | $5.2M | $2.6M | −$488,000 | $300,000 | −$815,000 | −$776,000 | −$722,000 | −$224,000 | −$724,000 | −$721,000 | −$30,000 |
| Research & development | $5.0M | $9.6M | $6.7M | $4.2M | $5.9M | $9.9M | $9.0M | $8.9M | $9.2M | $7.2M | $7.4M | $7.1M |
| Sales, general & admin | $15.8M | $19.5M | $18.8M | $19.3M | $17.1M | $9.8M | $7.7M | $6.4M | $8.6M | $7.1M | $5.8M | $4.2M |
| Total operating expenses | $20.9M | $28.2M | $25.5M | $23.5M | $23.1M | $19.7M | $15.9M | $15.3M | $17.9M | $14.3M | $12.5M | $11.3M |
| Operating income | −$13.7M | −$23.0M | −$22.9M | −$24.0M | −$22.8M | −$19.7M | −$16.7M | −$15.3M | −$17.9M | −$14.3M | −$13.2M | −$11.3M |
| Interest income | $1.4M | $1.4M | $1.5M | $1.7M | $1.0M | $1.3M | $1.0M | $1.2M | $1.2M | $843,000 | $743,000 | $593,000 |
| Interest expense | $696,000 | $830,000 | $884,000 | $901,000 | $957,000 | $998,000 | $1.1M | $1.1M | $1.1M | $952,000 | $109,000 | $105,000 |
| Income before taxes | −$20.2M | −$17.1M | −$20.7M | −$20.4M | $124.3M | −$12.0M | −$9.3M | −$30.3M | $7.4M | −$31.6M | −$16.6M | −$11.8M |
| Income taxes | — | $2,000 | −$215,000 | −$15.2M | $15.5M | — | −$680,724 | — | −$1.7M | $680,724 | $677,188 | $790,586 |
| Net income | −$20.2M | −$17.1M | −$20.5M | −$5.2M | $108.8M | −$12.0M | −$9.3M | −$30.3M | $7.4M | −$31.6M | −$16.6M | −$11.8M |
| EBITDA | −$18.7M | −$15.4M | −$18.7M | −$18.6M | $126.1M | −$10.2M | −$7.4M | −$28.4M | $9.2M | −$29.9M | −$15.8M | −$11.0M |
| EPS (diluted) | −$0.35 | −$0.30 | −$0.37 | −$0.11 | −$0.47 | −$0.24 | −$0.32 | −$0.63 | −$0.44 | −$0.52 | −$0.77 | −$0.43 |
| Gross margin | 63.3% | 59.1% | 47.7% | — | 75.0% | — | −16.2% | — | — | — | −25.5% | — |
| Operating margin | −120.0% | −264.1% | −422.7% | — | −5,698.0% | — | −348.6% | — | — | — | −467.7% | — |
| Net margin | −177.4% | −195.8% | −377.5% | — | 27,208.2% | — | −194.3% | — | — | — | −587.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ABEO's financial statements (latest annual report filed March 17, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ABEO financial results
In fiscal year 2025 (ended December 31, 2025), Abeona Therapeutics reported revenue of $5.8 million. It had net income of $71.2 million, a net profit margin of 1,223.1%. Diluted earnings per share came to −$1.19. Over five years revenue grew at an average rate of −10.3% a year.
See the ABEO stock overview for the latest quote and news, or the ABEO chart for price history and technical indicators.
ABEO income statement FAQ
What is Abeona Therapeutics's annual revenue?
Abeona Therapeutics reported total revenue of $5.8 million for fiscal year 2025, which ended on December 31, 2025.
Is Abeona Therapeutics profitable?
Yes. Abeona Therapeutics reported net income of $71.2 million in fiscal 2025, a net profit margin of 1,223.1%; its operating margin was −1,536.9%.
What is Abeona Therapeutics's gross margin?
Abeona Therapeutics's gross margin was 73.7% in fiscal 2025: for every $100 of revenue, Abeona Therapeutics kept $74 after the direct cost of its products and services.
How much does Abeona Therapeutics spend on research and development?
Abeona Therapeutics spent $26.8 million on research and development in fiscal 2025, 460.7% of revenue.
How fast is Abeona Therapeutics growing?
Revenue grew −10.3% a year on average over the last five fiscal years, from $10.0 million to $5.8 million.
What are Abeona Therapeutics's earnings per share?
Abeona Therapeutics earned $-1.19 per diluted share in fiscal 2025, compared with $-1.91 a year earlier.
When will Abeona Therapeutics report its next earnings?
Abeona Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Abeona Therapeutics's fiscal year end?
Abeona Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 17, 2026.